

NCT03173092 comparison:

Summary:
CHIA has 16 criteria while your personal folder has 16 criteria
Total found criteria: 16/16
Total not Found: 0/16
Total Extra: 13
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Participants must have completed 3 cycles of a     │ Participants must have completed 3 cycles of a     │
│ bortezomib-based induction regimen (as defined by  │ bortezomib-based induction regimen (as defined by  │
│ current NCCN guidelines) and have no evidence of   │ current NCCN guidelines) and have no evidence of   │
│ disease progression as defined by IMWG criteria    │ disease progression as defined by IMWG criteria    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participants with light chain and free light chain │ Participants with light chain and free light chain │
│ (FLC) only may be enrolled if they meet all the    │ (FLC) only may be enrolled if they meet all the    │
│ criteria for a diagnosis of MM                     │ criteria for a diagnosis of MM                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participants must be considered by their physician │ Participants must be considered by their physician │
│ eligible to receiving the IRD regimen              │ eligible to receiving the IRD regimen              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Eastern Cooperative Oncology Group (ECOG)          │ Eastern Cooperative Oncology Group (ECOG)          │
│ performance status and/or other performance status │ performance status and/or other performance status │
│ 0, 1, or 2 at time of enrollment                   │ 0, 1, or 2 at time of enrollment                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Failure to have fully recovered (that is, less     │ Failure to have fully recovered (that is, less     │
│ than or equal to [<=] Grade 1 toxicity) from the   │ than or equal to \[\<=\] Grade 1 toxicity) from    │
│ reversible effects of prior chemotherapy           │ the reversible effects of prior chemotherapy       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major surgery within 14 days before enrollment     │ Major surgery within 14 days before enrollment     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Radiotherapy within 14 days before enrollment (if  │ Radiotherapy within 14 days before enrollment (if  │
│ the involved field is small, 7 days will be        │ the involved field is small, 7 days will be        │
│ considered a sufficient interval between treatment │ considered a sufficient interval between treatment │
│ and administration of the ixazomib.)               │ and administration of the ixazomib)                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Central nervous system involvement                 │ Central nervous system involvement by MM           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Infection requiring systemic antibiotic therapy or │ Infection requiring systemic antibiotic therapy or │
│ other serious infection within 14 days before      │ other serious infection within 14 days before      │
│ study enrollment                                   │ study enrollment                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of current uncontrolled cardiovascular    │ Evidence of current uncontrolled cardiovascular    │
│ conditions, including uncontrolled hypertension,   │ conditions, including uncontrolled hypertension,   │
│ uncontrolled cardiac arrhythmias, symptomatic      │ uncontrolled cardiac arrhythmias, symptomatic      │
│ congestive heart failure, unstable angina, or      │ congestive heart failure, unstable angina, or      │
│ myocardial infarction within the past 6 months     │ myocardial infarction within the past 6 months     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Systemic treatment, within 14 days before the      │ Systemic treatment, within 14 days before the      │
│ first dose of ixazomib, with strong cytochrome     │ first dose of ixazomib, with strong cytochrome     │
│ P450 3A (CYP3A) inducers (rifampin, rifapentine,   │ P450 3A (CYP3A) inducers (rifampin, rifapentine,   │
│ rifabutin, carbamazepine, phenytoin,               │ rifabutin, carbamazepine, phenytoin,               │
│ phenobarbital), or use of Ginkgo biloba or St.     │ phenobarbital), or use of Ginkgo biloba or St.     │
│ John's wort                                        │ John's wort                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing or active systemic infection, active       │ Ongoing or active systemic infection, active       │
│ hepatitis B or C virus infection, or known human   │ hepatitis B or C virus infection, or known human   │
│ immunodeficiency virus positive                    │ immunodeficiency virus positive                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosed or treated for another malignancy within │ Diagnosed or treated for another malignancy within │
│ 2 years before study enrollment or previously      │ 2 years before study enrollment or previously      │
│ diagnosed with another malignancy and have any     │ diagnosed with another malignancy and have any     │
│ evidence of residual disease. Participants with    │ evidence of residual disease. Participants with    │
│ non-melanoma skin cancer or carcinoma in situ of   │ nonmelanoma skin cancer or carcinoma in situ of    │
│ any type are not excluded if they have undergone   │ any type are not excluded if they have undergone   │
│ complete resection                                 │ complete resection                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has greater than or equal to (>=) Grade 2          │ Has greater than or equal to (\>=) Grade 2         │
│ peripheral neuropathy, or Grade 1 with pain on     │ peripheral neuropathy, or Grade 1 with pain on     │
│ clinical examination during the screening period   │ clinical examination during the screening period   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ PD on first-line therapy                           │ PD on first-line therapy                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in other interventional clinical     │ Participation in other interventional clinical     │
│ trials, including those with other investigational │ trials, including those with other investigational │
│ agents not included in this trial, within 30 days  │ agents not included in this trial, within 30 days  │
│ of the start of this trial and throughout the      │ of the start of this trial and throughout the      │
│ duration of this trial. Non-interventional trials  │ duration of this trial. Non-interventional trials  │
│ (that is, observational trials) are permitted at   │ (that is, observational trials) are permitted at   │
│ any time point                                     │ any time point                                     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Agree to practice effective barrier contraception during the entire study treatment period and       │
│ through 90 days after the last dose of study drug, OR                                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Male participants, even if surgically sterilized (that is, status post-vasectomy), must agree to one │
│ of the following                                                                                     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female participants who                                                                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Are surgically sterile, OR                                                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Are postmenopausal for at least 1 year before the screening visit, OR                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have a diagnosis of a MM using current IMWG diagnostic criteria and have received 1 prior line  │
│ of therapy                                                                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the │
│ participant. (Periodic abstinence (example, calendar, ovulation, symptothermal, post-ovulation       │
│ methods\] and withdrawal are not acceptable methods of contraception)                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ If they are of childbearing potential, agree to practice 2 effective methods of contraception, at    │
│ the same time, from the time of signing the informed consent form through 90 days after the last     │
│ dose of study drug, OR                                                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Have previously been treated with ixazomib, or participated in a study with ixazomib whether treated │
│ with ixazomib or not                                                                                 │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ o Stem cell harvest and mobilization regimen is acceptable if clinically indicated, but must first   │
│ be confirmed by the Takeda Medical Monitor                                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the │
│ participant (periodic abstinence \[example, calendar, ovulation, symptothermal, post-ovulation       │
│ methods\] and withdrawal are not acceptable methods of contraception)                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must be transplant ineligible as determined by their physician, or if transplant eligible, not       │
│ expect to undergo transplant for at least 24 months after study enrollment                           │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛